Company intelligence / Profile preview

Avellino

Menlo Park, California, United Statesavellinorestaurant.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Avellino commercialized the world’s first DNA test to confirm genetic indicators of corneal dystrophies. Its lead gene therapy programs are in preclinical development. The company received FDA EUA as the third private company for a COVID‑19 RT-PCR diagnostic kit. It continues to expand its pipeline in ophthalmic genetics and precision medicine using AI/ML-powered genomics platforms.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Gene therapyCRISPR-based therapyMolecular diagnostics
Industry: Biotech

Drug pipeline

2 assets

Av CoV2

Commercial

Indications: COVID-19

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Avellino.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avellino.

Explore the full profile